GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: LON:GWP
- CUSIP: N/A
- Web: https://www.gwpharm.com/
- 50 Day Moving Avg: GBX 810.64
- 200 Day Moving Avg: GBX 650.91
- 52 Week Range: GBX 211 - GBX 950
- Trailing P/E Ratio: N/A
- P/E Growth: 0.000
- Net Margins: -1,673.22%
- Return on Equity: -48.31%
- Return on Assets: -42.39%
- Average Volume: 811,003 shs.
Frequently Asked Questions for GW Pharmaceuticals plc (LON:GWP)
What is GW Pharmaceuticals plc's stock symbol?
GW Pharmaceuticals plc trades on the London Stock Exchange (LON) under the ticker symbol "GWP."
Where is GW Pharmaceuticals plc's stock going? Where will GW Pharmaceuticals plc's stock price be in 2017?
1 brokerages have issued 12 month target prices for GW Pharmaceuticals plc's shares. Their forecasts range from GBX 835 to GBX 835. On average, they anticipate GW Pharmaceuticals plc's stock price to reach GBX 835 in the next twelve months. View Analyst Ratings for GW Pharmaceuticals plc.
Who are some of GW Pharmaceuticals plc's key competitors?
Some companies that are related to GW Pharmaceuticals plc include Amgen (AMGN), Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Kite Pharma (KITE), Exelixis (EXEL), TESARO (TSRO), BIOVERATIV INC (BIVV), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), Spark Therapeutics (ONCE), AveXis (AVXS) and Sarepta Therapeutics (SRPT).
Who are GW Pharmaceuticals plc's key executives?
GW Pharmaceuticals plc's management team includes the folowing people:
- Geoffrey W. Guy, Executive Chairman of the Board
- Justin Gover, Chief Executive Officer, Director
- Adam David George, Chief Financial Officer, Company Secretary, Director
- Christopher John Tovey, Chief Operating Officer, Executive Director
- Julian S. Gangolli, Executive Director
- James Julian Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director
- Cabot Brown, Non-Executive Independent Director
- Thomas Gerard Lynch, Non-Executive Independent Director
How do I buy GW Pharmaceuticals plc stock?
Shares of GW Pharmaceuticals plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is GW Pharmaceuticals plc's stock price today?
MarketBeat Community Rating for GW Pharmaceuticals plc (LON GWP)MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of GW Pharmaceuticals plc stock can currently be purchased for approximately GBX 716.60.
Consensus Ratings for GW Pharmaceuticals plc (LON:GWP) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||GBX 835|
Analysts' Ratings History for GW Pharmaceuticals plc (LON:GWP)
(Data available from 9/21/2015 forward)
|9/27/2016||Numis Securities Ltd||Reiterated Rating||Hold||GBX 835|
|3/14/2016||Peel Hunt||Reiterated Rating||Under Review|
Earnings History for GW Pharmaceuticals plc (LON:GWP)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for GW Pharmaceuticals plc (LON:GWP)
Current Year EPS Consensus Estimate: $-31.300 EPS
Dividend History for GW Pharmaceuticals plc (LON:GWP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for GW Pharmaceuticals plc (LON:GWP)Insider Trades by Quarter for GW Pharmaceuticals plc (LON:GWP)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/1/2016||Tom Lynch||Insider||Sell||2,074||GBX 790||£16,384.60|
|10/28/2016||Geoffrey Guy||Insider||Sell||31,682||GBX 790||£250,287.80|
|10/27/2016||Geoffrey Guy||Insider||Sell||138,318||GBX 804||£1,112,076.72|
|10/26/2016||Geoffrey Guy||Insider||Sell||130,000||GBX 808||£1,050,400|
|10/25/2016||Geoffrey Guy||Insider||Sell||125,000||GBX 809||£1,011,250|
|10/24/2016||Geoffrey Guy||Insider||Sell||68,900||GBX 824||£567,736|
|5/10/2016||Lynch ,Tom||Insider||Sell||50,000||GBX 441||£220,500|
|12/10/2015||Lynch ,Tom||Insider||Sell||4,270||GBX 451||£19,257.70|
|6/12/2015||James Noble||Insider||Sell||20,000||GBX 636||£127,200|
|6/11/2015||Stephen Wright||Insider||Sell||170,400||GBX 641||£1,092,264|
|2/9/2015||Christopher John Tovey||Insider||Sell||10,000||GBX 404.20||£40,420|
Headline Trends for GW Pharmaceuticals plc (LON:GWP)
Latest Headlines for GW Pharmaceuticals plc (LON:GWP)
GW Pharmaceuticals plc (GWP) Chart for Thursday, September, 21, 2017